Exelixis, Inc.

Stocks

EXEL

US30161Q1040

Market Closed - Nasdaq Other stock markets 01:30:00 10/06/2026 am IST			5-day change	1st Jan Change
52.99 ^USD	+2.42%		+9.17%	+20.90%

09/06	Exelixis, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 10:40 AM
03/06	Exelixis, Inc. Presents at Jefferies Global Healthcare Conference 2026, Jun-03-2026 11:05 AM

Transcript : Exelixis, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 12

Published on 03/11/2026 at 10:35 pm IST - Modified on 03/11/2026 at 11:35 pm IST

S&P Capital IQ

Presenter Speech
Etzer Darout (Analysts)

Hello again, everyone. I'm Etzer Darout, senior biotech analyst at Barclays. It's my pleasure to have Exelixis with us. With us today, we have Senior Vice

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Exelixis, Inc.

09/06	Exelixis, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 10:40 AM
03/06	Exelixis, Inc. Presents at Jefferies Global Healthcare Conference 2026, Jun-03-2026 11:05 AM
01/06	Wall Street Starts June on Edge
30/05	Exelixis says Cabometyx reduces risk of progression or death by 74% in non-functional net, 60% in functional net	RE
30/05	Exelixis Announces Results from Subgroup Analysis of Phase 3 Cabinet Pivotal Trial Evaluating Cabometyx in Non-Functional and Functional Neuroendocrine Tumors At Asco 2026	CI
28/05	Exelixis, Inc. Presents at Bernstein 42nd Annual Strategic Decisions Conference, May-27-2026 03:30 PM
22/05	Exelixis, Inc. Announces Presentations of Cabometyx and Zanzalintinib At 2026 2026 Annual Meeting	CI
21/05	Exelixis, Inc. Presents at Stifel 2026 Targeted Oncology Virtual Forum, May-20-2026 01:30 PM
20/05	Exelixis Insider Sold Shares Worth $1,745,050, According to a Recent SEC Filing	MT
19/05	Exelixis, Inc. Presents at RBC Capital Markets Global Healthcare Conference 2026, May-19-2026 09:00 AM
19/05	Merck to Collaborate With Exelixis on Phase 3 Colorectal Cancer Trial	MT
19/05	Exelixis, Inc. Announces Clinical Development Collaboration with Merck for Phase 3 Stellar-316 Pivotal Trial for Patients with Colorectal Cancer	CI
12/05	Exelixis, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 10:00 AM
11/05	Exelixis Insider Sold Shares Worth $2,742,600, According to a Recent SEC Filing	MT
11/05	Exelixis Insider Sold Shares Worth $949,164, According to a Recent SEC Filing	MT